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FINAL EXAMINATION DURATION 
PHA406 – Therapeutics B 
 
Reading Time: 10 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
Section A: Answer all FIVE (5) short-answer questions.  This section should be answered in the 
Answer Booklet provided.  Marks for each section are indicated.  Suggested time allocation: 90 
min.  Total marks 50 
Section B: Answer all Case Study Questions (5). Total No of Marks for this section: 50. This 
section should be answered in the Answer Booklet provided.  Answer all questions.  Marks for 
each question are indicated.  Suggested time allocation: 90 min 
Students are allowed to bring their own Australian Medicines Handbook.  It can be flagged or 
highlighted but no additional annotation or material inserted. 
EXAM CONDITIONS 
 
You may begin writing from the commencement of the examination session.  The reading time 
indicated above is provided as a guide only. 
This is a RESTRICTED OPEN BOOK examination 
No calculators are permitted 
No handwritten notes are permitted 
Hard copy, unannotated English translation dictionary only 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 
Lecture Textbook/s (Unannotated) 
 
1 x 8 Page Book 
1 x 20 Page Book 
1 x Scrap Paper 
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Section A 
 
Answer all FIVE (5) Short-Answer Questions 
This section should be answered in the Answer Booklet provided. Marks for 
each section are indicated. Suggested time allocation: 90 min 
Total marks 50 
 
Question 1 
Describe the aetiology, pathophysiology, clinical presentations and 
management/treatment plan(s) for: 
A. Hyperthyroidism 
B. Hyperparathyroidism 






Discuss the differences between open-angle glaucoma and angle-closure 
glaucoma.  Your discussion should include the aetiology, pathogenesis, treatment 
options, and an explanation why angle-closure glaucoma-- but not open-angle 
glaucoma— can sometimes become a medical emergency (acute crisis). 






Discuss the pathogenesis, clinical presentations and ideal management plans for 
bipolar disorder.  In your discussion, identify if (and how) each component is 
different from major (unipolar) depression. 
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A patient with longstanding Parkinson’s disease finds that she is no longer getting 
the same benefit from her levodopa/benserazide combination. She finds that she 
in unable to rise from a chair because of stiffness well before her next dose is due. 
A. Briefly discuss the pathophysiology of Parkinson’s disease. 
 (4 marks) 
B. How does levodopa act to alleviate the symptoms of Parkinson’s 
disease and what are the advantages of using levodopa/benserazide 
combination? 
 (3 marks) 
C. Explain why this patient developed these symptoms. Suggest TWO (2) 
different modifications in her treatment that may be useful to resolve her 
problem. 




Describe 5 common causes of insomnia and recommend appropriate 
pharmacological and nonpharmacological therapies for the management and 
prevention of insomnia. 
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Section B 
 
Answer All Case Study Questions (5) 
This section should be answered in the Answer Booklet provided. Marks for 
each question are indicated. Suggested time allocation: 90 min 
Total marks 50 
 
Mrs AB, a 28 year-old female, moved to Darwin two weeks ago for her new job.  A 
few weeks before Mrs AB relocated, she started feeling restless, anxious, and 
unable to focus on any particular task for an extended period of time.  In the past few 
days Mrs AB also experiences symptoms of insomnia, lack of appetite, and generally 
feels unwell 
Mrs AB experiences a few episodes of anxiety/panic attack during work-related 
meetings, including symptoms of palpitation, dry mouth and sweaty palms.  Social 
isolation calms her anxiety and she is avoiding social occasions whenever possible.  
This includes avoiding her own family. 
 
During a medical examination, Mrs AB’s vital signs are relatively stable: BP 





• Anxiety/panic disorder 
• Major depression (diagnosed 10 years ago, currently well-controlled) 
• Asthma (last major exacerbation approximately 3 months ago) 
• Dysmenorrhoea (irregular menstrual cycle) 
 
 
Social and Family History: 
• Married, live with husband and have no children 
• Daily alcohol use (partly to reduce anxiety) 
• Smoking approximately 10 cigarettes per day (currently attempt to quit) 
• Overweight (BMI=32) 
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Medication History (Note: Poor compliance) 
Risperidone 4mg once daily 
Duloxetine 60mg once daily 
Symbicort 200/6mcg turbuhaler 1-2 puffs prn 




Mrs AB’s doctor also ordered a few tests and the results are as follow: 
Test Result (mmol/L) Reference Range 
Total cholesterol 5.5 < 5.5 
LDL 3.6 2 – 3.4 
TG 2.1 < 1.7 
HDL 0.9 1 – 2.2 







Suggest THREE (3) most likely diagnoses for Mrs AB’s current conditions.  Justify 
your answer with reference to the information provided above and Mrs AB’s risk 
factors. 






Identify and discuss additional diagnostic tests or examination tools that can be used 
to help confirm or exclude the potential diagnoses you have suggested in Question 
1. 
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Question 3  
Mrs AB has a medical history of 3 different mental health disorders – schizophrenia, 
anxiety disorder, and major depression.  Briefly discuss and compare the following 
aspects of schizophrenia and anxiety disorder. 
• Aetiology 
• Clinical presentations 
• Prognosis and aim of therapy 






What do the results from Mrs AB’s laboratory tests indicate? 






Propose immediate and long-term treatment/management plans for Mrs AB.  Justify 
your recommendations and identify any differences between the immediate and 
long-term plans. 











End of Examination 
 
